An investigational Zika virus vaccine appeared safe and immunogenic in three Phase 1 clinical trials.
The vaccine was well-tolerated and induced an immune response, according to results published in the Lancet. The vaccine is being developed at the Walter Reed Army Institute of Research.
The initial studies involved 67 adult patients, with 55 receiving the investigational vaccine and 12 receiving placebos. Researchers detected antibodies to the virus in more than 90 percent of patients receiving the experimental drug within four weeks of the final dose.